LLY - MeiraGTx Positive Data And Other News: The Good Bad And Ugly Of Biopharma
MeiraGTx reports encouraging data for ocular gene therapy
MeiraGTx (MGTX) announced initial data from its ongoing clinical trial of AAV-RPGR, for treating patients with X-linked retinitis pigmentosa (XLRP) with genetically confirmed variants in the RPGR gene. The dose escalation phase of the trial demonstrated significant improvement in vision. MeiraGTx is partnering with Janssen Pharmaceuticals Inc., a part of Johnson & Johnson (JNJ) group for this program.
The ongoing Phase 1/2 MGT009 clinical trial comprises three phases which are dose-escalation, dose-confirmation, and dose-expansion. The dose escalation phase had 10 adult patients who were given